Inventiva in brief
Centered around assets spun out from Abbott six years ago, Inventiva today is a diversified, clinical stage biopharmaceutical company with an advanced product pipeline in fibrotic and orphan diseases.
The Company’s lead compounds are:
- Lanifibranor, a next generation pan-PPAR agonist in clinical development for non-alcoholic steato-hepatitis (NASH) and systemic sclerosis (SSc), and
- Odiparcil for mucopolysaccharidosis VI (MPS VI), a lysosomal storage disease.
Lanifibranor and Odiparcil each received orphan drug designation from the U.S. Food and Drug Administration and European Medicines Agency for SSc and MPS VI, respectively.
In addition to the Company’s two lead compounds, Inventiva has a number of highly promising early stage programs targeting novel pathways and mechanisms of action to treat cancer and fibrotic disease.
Listed on Euronext Paris since 2017, Inventiva continues to execute on its strategic objectives, is well-capitalized, and enjoys the support of specialized healthcare investors in the U.S. and in Europe.